Spearheading Development of Gold Standard Donor Screening, Testing & Management to De-Risk Manufacturing, Improve Product Consistency & Performance & Meet Clinical Demand of High Quality Donor Material For Allogeneic Cell Therapies
Donor quality and strategy is the difference between promising allogeneic therapies and commercially viable products.
As more allogeneic programs progress into later-stage development, manufacturers are seeing first-hand how donor variability impacts yield, product consistency, cost of goods, and clinical performance. At the same time, regulators are demanding greater control and traceability of donor starting material, while investors increasingly expect evidence of scalable manufacturing. With competition from in vivo therapies intensifying, the industry can no longer afford to treat donor selection as a siloed upstream decision.
Fit-for-purpose donor strategies are emerging as a critical competitive advantage.
That's why the 4th Donor Selection & Cell Source Summit returns as the only dedicated forum focused exclusively on donor sourcing, screening, characterization, testing, and management for allogeneic cell therapies.
Join leaders from Bristol Myers Squibb, Senti Biosciences, Cellectis, Mesoblast, ImmuneBridge, Ernexa Therapeutics, and Indapta Therapeutics to explore how donor biology influences the entire therapy lifecycle. Through cross-functional discussions spanning process development, R&D, manufacturing, clinical development, and supply chain, you'll gain practical strategies to improve product performance, strengthen clinical outcomes, and improve manufacturing efficiency. Discover how the industry's leading innovators are transforming donor material from a source of variability into a driver of scalability, regulatory readiness, and commercial success.
Make your manufacturing processes and clinical outcomes reap the rewards of an optimized donor selection strategy.
This meeting will provide a good avenue to discuss the importance of donor selection and cell source for both the conventional and unconventional T-cells for future immunotherapy development. It also allows greater networking opportunities with other key players from the industry and medical organizations.
Research Fellow, Olivia Newton-John Cancer Research Institute, 2026 Speaker
The intimate group setting enabled ready connection and discussion on donor selection strategies and methodologies.
Senior Director, Senti Biosciences, 2025 Attendee
It was great to know people in the same field as us and the opportunity to learn from each other bottle's necks, advances and current innovation to make cell and gene therapies available for everyone!
Supervisor, Genentech, 2025 Attendee
Explore the Full Event Guide
- Discover donor selection strategies from Cellectis, Mesoblast, Atara, and Caribou to improve clinical outcomes
- Explore donor sourcing from cord blood, PBMCs, and iPSCs to benchmark strategies, and gain clarity on where the field is moving
- Review the full agenda, speakers, and sessions to align team priorities
- Identify valuable networking opportunities to maximize connections with peers and providers
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover practical strategies to improve donor selection, reduce variability, and strengthen manufacturing and clinical outcomes.
Partner With Us
Position your brand alongside the organizations helping allogeneic developers build fit-for-purpose donor strategies.
Join Microbiome Experts
Connect with experts across donor operations, manufacturing, clinical development, and supply chain to build valuable partnerships.